BioCentury
ARTICLE | Company News

Dr. Reddy's, XenoPort strike deal for psoriasis therapy

March 29, 2016 1:21 AM UTC

XenoPort Inc. (NASDAQ:XNPT) granted Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) exclusive, U.S. rights to develop and commercialize XP23829, which has completed a Phase II trial to treat moderate to severe chronic plaque-type psoriasis. The compound is an oral prodrug of monomethyl fumarate (MMF) that induces and activates the nuclear factor (erythroid-derived 2)-like 2 ( NFE2L2; NRF2) pathway.

XenoPort will receive $47.5 million up front and is eligible for $190 million in regulatory milestones and $250 million in commercial milestones, plus royalties up to the mid-teens. XenoPort also will receive $2.5 million upon the transfer of clinical trial materials to Dr. Reddy%27s. ...